New gene therapy trial hopes to slow duchenne muscular dystrophy
Disease control
Recruiting now
This study tests a gene therapy called delandistrogene moxeparvovec in 83 people with Duchenne muscular dystrophy (DMD). The goal is to see if it is safe and helps the body produce a key muscle protein. Participants include both children and adults who can walk or use a wheelchai…
Phase: PHASE1 • Sponsor: Sarepta Therapeutics, Inc. • Aim: Disease control
Last updated May 06, 2026 16:00 UTC